Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 2/2016

01.02.2016 | Research Article

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

verfasst von: J. Remon, D. Alvarez-Berdugo, M. Majem, T. Moran, N. Reguart, P. Lianes

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The prognostic value of EGFR mutation in lung cancer patients with brain metastases is uncertain and therapeutic efficacy with EGFR TKI is limited. Looking for biomarkers closely related with early tumor changes and brain metastases in non-small cell lung cancer is warranted. MicroRNAs (miRNAs) are frequently deregulated in lung cancer. The objective of this study was to investigate whether some miRNAs are related with brain metastasis risk in EGFR-mutant non-small cell lung cancer patients.

Materials and methods

miRNA quantification was retrospectively performed in formalin-fixed, extracranial paraffin-embedded adenocarcinoma tumor tissue available from 17 human samples of advanced non-small cell lung cancer patients. Samples were classified as brain metastasis group (5 EGFR-mutant patients with initial BM, EGFRm-BM+; and 6 EGFR wild-type patients with initial BM) and the control group (6 EGFR-mutant NSCLC patients without BM). The RNA obtained was preamplified and retro-transcribed, and the miRNA was quantified with the TaqMan OpenArray Human MiRNA Panel in the QuantStudio™ 12 K Flex Real-Time PCR system.

Results

miRNA-197 and miRNA-184 showed a significant higher expression in EGFRm-BM+ group than in the control group (p = 0.017 and p = 0.01, for miRNA-197 and miRNA-184, respectively), with a trend toward overexpression in BM group compared with the control group (p = 0.08 and p = 0.065, for miRNA-197 and miRNA-184, respectively), without differences in expression in BM group according to EGFR mutational status (EGFR wild type vs. EGFR-mutant: p = 0.175 and p = 0.117, for miRNA-197, miRNA-184 respectively).

Conclusions

miRNA-197 and miRNA-184 are overexpressed in EGFR-mutant patients with BM and they might be a new biomarker for stratifying the risk of BM in this subpopulation.
Literatur
1.
Schoutten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastasis in a cohort of patients with carcinoma of breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.CrossRef
2.
Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242:882–8.CrossRefPubMed
3.
Pw Sperduto, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–25.CrossRef
4.
Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8:344–56.PubMedCentralPubMed
5.
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006.PubMedCentralCrossRefPubMed
6.
Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. Future Oncol. 2015;28:1–13.
7.
Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119:1491–4.CrossRefPubMed
8.
Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T, Iwasawa T, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer. 2012;77:64–9.CrossRefPubMed
9.
Lee DW, Shin DY, Kim JW, Keam B, Kim TB, Kim HJ, et al. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma of patients with brain metastasis: integrating with lung specific GPA score. Lung Cancer. 2014;86:363–8.CrossRefPubMed
10.
Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18:938–44.CrossRefPubMed
11.
Omuro M, Kris MG, Miller VA, Franceschi F, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with non-small cell lung cancer after response to gefitinib. Cancer. 2005;103:2344–8.CrossRefPubMed
12.
Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non-small cell lung cancer. Cancer. 2010;116:1336–43.CrossRefPubMed
13.
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77:556–60.CrossRefPubMed
14.
Porta R, Sánchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37:624–31.CrossRefPubMed
15.
Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10:156–63.PubMedCentralCrossRefPubMed
16.
Kim DW, Yang JCH, Cross D, Billard P, Yang P, Yates J, et al. Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases. ESMO Conference 2014, abstract p 456.
17.
Alsidawi S, Malek E, Driscoll JJ. MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. Int J Mol Sci. 2014;15:10508–26.PubMedCentralCrossRefPubMed
18.
McDermott R, Gabikian P, Sarvaiya P, Ulasov I, Lesniak MS. MicroRNAs in brain metastases: big things come in small packages. J Mol Med. 2013;91:5–13.CrossRefPubMed
19.
Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastasis in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. Lung Cancer. 2015;88:108–11.CrossRefPubMed
20.
Hendriks LE, Smit EF, Vosse BA, Mellema WW, Heideman DA, Bootsma GP, et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer. 2014;84:86–91.CrossRefPubMed
21.
Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naïve non-small cell lung cancer. Cancer. 2012;118:4502–11.PubMedCentralCrossRefPubMed
22.
Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, et al. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2009;135:1647–54.CrossRefPubMed
23.
Shin DY, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9:195–9.CrossRefPubMed
24.
Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009;15:4829–37.PubMedCentralCrossRefPubMed
25.
Pöttegen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, et al. Prophylactic cranial irradiation in operable stage IIIA non-small cell lung cancer treated with neoadjuvant chemo-radiotherapy: results from a German multicentre randomized trial. J Clin Oncol. 2007;25:4987–92.CrossRef
26.
Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29:272–8.PubMedCentralCrossRefPubMed
27.
Li N, Zeng ZF, Wang SY, Ou W, Ye X, Li J, et al. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 non-small-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Ann Oncol. 2015;26:504–9.CrossRefPubMed
28.
Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer. Neuro Oncol. 2012;12:1193–9.CrossRef
29.
Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18:4406–14.PubMedCentralCrossRefPubMed
30.
Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16:5873–82.PubMedCentralCrossRefPubMed
31.
Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, et al. non-small cell lung cancers with kinase domain mutations in epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 2006;66:9061–8.
32.
Shepherd F, Altorki N, Eberhardt W, O’Brien M, Spigel D, Crino L, et al. Adjuvant erlotinib versus placebo in non-small cell lung cancer patients with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. J Clin Oncol. 2014;32 (suppl; abstr 7513).
33.
Kim DW, Yang JCH, Chen K, Cheng Z, Yin L, Martin PD, et al. AZD3759, an EGFR inhibitor with blood brain barrier penetration for the treatment of non-small cell lung cancer with brain metastasis: preclinical evidence and clinical cases. J Clin Oncol. 2015;33 (suppl, abstr 8016).
34.
Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4:575–86.PubMedCentralPubMed
35.
Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizi M, Biffoni M, et al. Antitumor effect of miR-197 targeting in p53 wild type lung cancer. Cell Death Differ. 2014;21:774–82.PubMedCentralCrossRefPubMed
36.
Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-98 and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009;7:1234–43.PubMedCentralCrossRefPubMed
37.
Hamada S, Satoh K, Miura S, Hirota M, Kanno A, Masamune A, et al. miR-197 induces epithelial–mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol. 2013;228:1255–63.CrossRefPubMed
38.
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P. Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.PubMedCentralCrossRefPubMed
39.
Liu Z, Mai Ch, Yang H, Zhen Y, Yu X, Hua S. Candidate tumor suppressor CCDC19 regulates miR-184 direct targeting c-MYC thereby suppressing cell growth in non-small cell lung cancers. J Cell Mol Med. 2014;18:1667–79.PubMedCentralCrossRefPubMed
40.
Yuan Q, Gao W, Liu Bo, Ye W. Upregulation of miR-184 enhances the malignant biological behaviour of human glioma cell line A172 by targeting FIH-1. Cell Physiol Biochem. 2014;34:1125–36.CrossRefPubMed
41.
Cui QC, Liu WD, Zhu JX, Wang YH, Wang ZG. MicroRNA-184 promotes proliferation ability of glioma cells by regulating FOXO3. Asian Pac J Trop Med. 2014;7:776–9.CrossRefPubMed
42.
Zhong KZ, Chen WW, Hu XY, Jiang AL, Zhao J. Clinico-pathological and prognostic significance of microRNA-107 in human non small cell lung cancer. Int J Clin Exp pathol. 2014;7:4545–51.PubMedCentralPubMed
43.
Wang WX, Danaher RJ, Miller CS, Berger JR, Nubia VG, Wilfred BS, et al. Expression of miR-105/107 family of microNRAs in human tissues and cultured brain cells. Genomics Proteomics Bioinform. 2014;12:19–30.CrossRef
44.
Liu J, Wang X, Yang X, Liu Y, Shi Y, Ren J. miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells. Cancer Lett. 2014;347:98–104.CrossRefPubMed
45.
Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, et al. MicroRNA-328 is associated with non-small cell lung cancer brain metastasis and mediates NSCLC migration. Int J Cancer. 2011;129:2621–31.PubMedCentralCrossRefPubMed
46.
Chen L, Xu S, Xu H, Zhang JF, Ning JF, Wang SF. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med Oncol. 2012;29:1673–80.CrossRefPubMed
47.
Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stem DF, et al. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastases. Cancer Res. 2013;73:5053–65.PubMedCentralCrossRefPubMed
48.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011;18:74–82.PubMedCentralPubMed
49.
Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008;68:10128–36.CrossRefPubMed
50.
Gadgeel SM, Wozniak A. Preclinical rational for PI3K/AKT/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer. 2013;14:322–32.CrossRefPubMed
51.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279–90.PubMedCentralCrossRefPubMed
Metadaten
Titel
miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers
verfasst von
J. Remon
D. Alvarez-Berdugo
M. Majem
T. Moran
N. Reguart
P. Lianes
Publikationsdatum
01.02.2016
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1347-2

Weitere Artikel der Ausgabe 2/2016

Clinical and Translational Oncology 2/2016 Zur Ausgabe

Research Article

Pemetrexed for primary central nervous system lymphoma in the elderly

Research Article

Expression and clinical significance of cortactin protein in ovarian neoplasms

Research Article

Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma

Research Article

Yes-associated protein (YAP) expression is involved in epithelial–mesenchymal transition in hepatocellular carcinoma

Brief Research Article

Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer

Research Article

The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise